-transparent.png){kind=logo}
The combination of 2'-deoxycoformycin (DCF), a potent adenosine deaminase (ADA) inhibitor, and 9-beta-D-arabinofuranosyladenine (Ara-A) was used in a patient with acute nonlymphocytic leukemia refractory to all conventional modes of therapy. DCF was given by periodic iv injections to ablate ADA activity. Ara-A was given by continuous iv infusion at an initial dose of 1.5 mg/kg/day, with progressive increases to 6 mg/kg/day. With adequate ADA suppression (less than 2 x 10(-2) mumols of inosine/hr/10(6)h cells), the Ara-A decreased the absolute peripheral blood myeloblast count from 36,332 to 780/microliter. The patient experienced no renal, hepatic, or neurologic complications during therapy.
D P Gray, and
M R Grever, and
M F Siaw, and
M S Coleman, and
S P Balcerzak
January 1986,
Advances in experimental medicine and biology,
D P Gray, and
M R Grever, and
M F Siaw, and
M S Coleman, and
S P Balcerzak
August 1986,
Current eye research,
D P Gray, and
M R Grever, and
M F Siaw, and
M S Coleman, and
S P Balcerzak
July 1977,
Cancer research,
D P Gray, and
M R Grever, and
M F Siaw, and
M S Coleman, and
S P Balcerzak
September 1982,
Cancer research,
D P Gray, and
M R Grever, and
M F Siaw, and
M S Coleman, and
S P Balcerzak
April 1976,
Cancer research,
D P Gray, and
M R Grever, and
M F Siaw, and
M S Coleman, and
S P Balcerzak
January 1968,
Chemotherapia,
D P Gray, and
M R Grever, and
M F Siaw, and
M S Coleman, and
S P Balcerzak
May 1982,
Cancer research,
D P Gray, and
M R Grever, and
M F Siaw, and
M S Coleman, and
S P Balcerzak
September 1977,
Cancer research,
D P Gray, and
M R Grever, and
M F Siaw, and
M S Coleman, and
S P Balcerzak
February 1974,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
D P Gray, and
M R Grever, and
M F Siaw, and
M S Coleman, and
S P Balcerzak
February 1981,
Cancer research,
